Cladribine for multiple sclerosis: review and current status.
about
New and emerging disease modifying therapies for multiple sclerosisCladribine tablets for the treatment of relapsing-remitting multiple sclerosisInfection risk in patients on multiple sclerosis therapeutics.Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosisNew oral disease-modifying therapies for multiple sclerosis.Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosisEscalating immunotherapy of multiple sclerosis.Chemotherapeutics in the treatment of multiple sclerosis.Chronic cladribine administration increases amyloid beta peptide generation and plaque burden in mice.Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis.Cladribine: an investigational immunomodulatory agent for multiple sclerosis.Disease-modifying drugs for multiple sclerosis: current and future aspects.Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits.Immunosuppressive agents in multiple sclerosis.Cladribine in indolent non-Hodgkin's lymphoma.Treating multiple sclerosis with monoclonal antibodies: a 2010 update.Immunomodulatory drug treatment in multiple sclerosis.Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal.An update on cladribine for relapsing-remitting multiple sclerosis.Effects of 2-chlorodeoxyadenosine (Cladribine) on primary rat microglia.Cladribine to Treat Relapsing Forms of Multiple Sclerosis.Synthesis and Functional Investigations of Computer Designed Novel Cladribine-Like Compounds for the Treatment of Multiple Sclerosis.Cladribine in aggressive forms of multiple sclerosis.Immunotherapy of multiple sclerosis.
P2860
Q22242305-7AE53FD7-E045-4F4F-BEED-DB1506B0AB25Q28281816-EF69FF99-DD8D-43E5-AB6E-FD4E23E64475Q30908652-AE291467-3ECD-4012-B131-FEFF0661D91FQ33802186-E058BDF1-2C72-45E1-8EE6-A03EF67B8281Q34076398-AB41CD43-0D61-4BFE-831C-184CD28F8213Q34100842-6CE82469-9CD2-4D49-BCCB-EA07D59ACD89Q34184148-3F8404FD-E6CE-4F97-A504-399F3A8B89C6Q34409100-558111E8-A085-4FFD-9FF7-AC5A0B38A16AQ34409536-14B30C13-7E9A-4632-833B-C3F47997F4C6Q34441015-AFAB71AD-8BBC-406E-997C-D319C06596BAQ34630494-CC55D0CE-BE82-482B-9A84-F47E2CEA8283Q36598122-1866C908-9FE2-4209-BC76-EA96085F6045Q36613906-592529FE-7ADC-421E-AA06-789B8D3159FDQ36648175-457D73EE-FFC7-4BE9-9D91-ECEC7A0C2637Q36963189-CD936CDB-B650-41D2-9439-CEB8136C1E98Q37134422-AFCA4EBE-E5AC-4BDD-9BD7-0BFC6EC81FFAQ37737305-6C0DBDA5-34A0-4C0C-A6A1-593C68F1729AQ37785554-9FAC3BAD-D8F5-4F14-8509-80966A624938Q38534132-8E53F60A-3F11-405E-B9A4-AD649204E2AFQ38600051-1A083ACA-1F96-4F16-A2BA-900665F54959Q42660093-9E2EF567-DD3A-494A-A060-663AAFF928A7Q47425049-3AC315F0-A76A-4E81-AC36-B6DA7CA64C57Q47901567-9AC1DDD5-478B-4671-A67C-E85A5E5D16D9Q48150889-9F5AD028-A4D4-4C60-9E6F-6C6D45CFAEFEQ54502086-97D7933E-A574-40F7-924B-B9D1EDBD49A3
P2860
Cladribine for multiple sclerosis: review and current status.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Cladribine for multiple sclerosis: review and current status.
@ast
Cladribine for multiple sclerosis: review and current status.
@en
type
label
Cladribine for multiple sclerosis: review and current status.
@ast
Cladribine for multiple sclerosis: review and current status.
@en
prefLabel
Cladribine for multiple sclerosis: review and current status.
@ast
Cladribine for multiple sclerosis: review and current status.
@en
P2860
P356
P1476
Cladribine for multiple sclerosis: review and current status.
@en
P2093
Jack C Sipe
P2860
P304
P356
10.1586/14737175.5.6.721
P577
2005-11-01T00:00:00Z